SWOG clinical trial number
SWOG-9429
Phase II Trial of Carboplatin and VP-16 With Concurrent For Poor-Risk Stage III Non-Small Cell Lung Carcinoma
Closed
Phase
Accrual
100%
Published
Abbreviated Title
Phase II Trial of Carboplatin and VP-16 With Concurrent For Poor-Risk Stage III Non-Small Cell Lung Carcinoma
Activated
08/15/1994
Closed
09/01/1995
Research committees
Lung Cancer
Publication Information Expand/Collapse
2019
1998
Southwest Oncology Group phase II trial of concurrent carboplatin, etoposide and radiation for poor-risk stage III non-small cell lung cancer.
1997
A Southwest Oncology Group (SWOG) phase II trial: carboplatin and VP-16 with concurrent radiation for poor risk stage III non-small cell lung cancer.
Other Clinical Trials
SWOG Clinical Trial Number
S2414
INcorporating pathologic reSponse in patIents with early staGe lung cancer to optimize immunotHerapy in the adjuvanT setting (INSIGHT)
Research Committee(s)
Lung Cancer
Symptom Control and Quality of Life
Activated
03/14/2025
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
A082002
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Research Committee(s)
Lung Cancer
Activated
12/21/2021
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-LU007
RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Research Committee(s)
Lung Cancer
Activated
08/17/2020
Open